Scarica l'app Stockscreener
6.36
5.22%
-0.35
Dopo l'orario di chiusura:
6.40
0.04
+0.63%
Precedente Chiudi:
$6.71
Aprire:
$6.52
Volume 24 ore:
1.75M
Relative Volume:
0.97
Capitalizzazione di mercato:
$666.03M
Reddito:
$69.65M
Utile/perdita netta:
$-81.27M
Rapporto P/E:
-6.9982
EPS:
-0.9088
Flusso di cassa netto:
$-79.45M
1 W Prestazione:
+6.35%
1M Prestazione:
-4.07%
6M Prestazione:
-15.31%
1 anno Prestazione:
+30.06%
Intervallo 1D:
$6.32
$6.59
Intervallo di 1 settimana:
$5.70
$7.3925
Portata 52W:
$3.84
$11.50
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.36 | 702.68M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-03-17 | Iniziato | Craig Hallum | Buy |
| 2023-02-06 | Aggiornamento | Needham | Hold → Buy |
| 2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Downgrade | Needham | Buy → Hold |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-20 | Reiterato | Needham | Buy |
| 2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-12 | Reiterato | Needham | Buy |
| 2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Iniziato | BofA/Merrill | Neutral |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Morgan Stanley | Overweight |
| 2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test - Investing.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com UK
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
BTIG cuts Personalis stock price target on lab sector valuation - Investing.com
BTIG cuts Personalis stock price target on lab sector valuation By Investing.com - Investing.com Nigeria
Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim Remains a Buy on Personalis (PSNL) - The Globe and Mail
Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Personalis Q1 Earnings Call Highlights - Barchart.com
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Q1 2026 Personalis Inc Earnings Call Transcript - GuruFocus
Guggenheim Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Needham reiterates Personalis stock rating citing MRD growth By Investing.com - Investing.com Australia
Personalis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham reiterates Personalis stock rating citing MRD growth - Investing.com UK
Personalis, Inc. (PSNL) Stock Analysis: Navigating a Promising 88% Upside in Healthcare Genomics - DirectorsTalk Interviews
Personalis: Q1 Earnings Snapshot - theheraldreview.com
Personalis Reports First Quarter Results and Recent Highlights - BioSpace
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss - Investing.com
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss By Investing.com - Investing.com South Africa
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):